Anebulo Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value Measurements

Fair Value Measurements

12 Months Ended

Jun. 30, 2025

Note 12. Fair Value Measurements

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

	Level 1		Level 2		Level 3		Total
	June 30, 2025
	Level 1		Level 2		Level 3		Total

Money market fund	$	11,373,304	$	–	$	–	$	11,373,304
Total	$	11,373,304	$	–	$	–	$	11,373,304

	Level 1		Level 2		Level 3		Total
	June 30, 2024
	Level 1		Level 2		Level 3		Total

Money market fund	$	2,671,889	$	–	$	–	$	2,671,889
Total	$	2,671,889	$	–	$	–	$	2,671,889

There were no financial instruments that were measured at fair value on a recurring basis as of June 30, 2025 and 2024. Money market funds are classified as Level 1 of the fair value hierarchy because they are valued using quoted market prices in an active market. During the periods presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value. There were no transfers within the hierarchy during either of the years ended June 30, 2025 and 2024, respectively.